Literature DB >> 12871330

Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2.

A Sahni1, C W Francis.   

Abstract

Fibroblast growth factor-2 (FGF-2) binds to fibrin(ogen) with high affinity, and fibrinogen potentiates FGF-2-stimulated proliferation of endothelial cells. Because plasmin degrades fibrin(ogen) physiologically and could liberate growth factor from fibrin deposits or alter its activity, we have now investigated the effect of plasmic degradation on the activity of fibrin(ogen)-bound FGF-2. Fibrinogen with bound FGF-2 was incubated with plasmin, the products characterized by SDS-PAGE, and the proliferative activity determined by (3)H-thymidine incorporation into endothelial cells. Before plasmin exposure, proliferation was increased 3.7 +/- 0.6-fold with fibrinogen-bound FGF-2 compared with medium alone (P < 0.005). Plasmic degradation resulted in progressive decrease in the proliferative capacity, with the 60-min digest showing predominantly fragment D1 and E and (3)H-thymidine uptake of only 1.2 +/- 0.2-fold, significantly less than the activity of an equal concentration of free FGF-2 (P < 0.02). However, further degradation increased activity, and proliferation with a 90-min digest increased to 2.6 +/- 0.5-fold, significantly greater than the 60-min digest (P < 0.02). Plasmic degradation in the presence of 10 mm calcium chloride prevented degradation of D1 to D2 and D3, and the activity did not increase with extended degradation. Immunoprecipitation of the digests with antifibrinogen antibody showed 70 +/- 8% of fibrinogen-bound FGF-2 in the presence of calcium but only 15 +/- 4% in its absence, indicating that cleavage of D1 to D2 and D3 is critical in binding. Fragment D1 and D2, but not D3, bound to a column containing immobilized FGF-2, indicating that a binding site is lost upon degradation to D3. The results demonstrate that plasmic degradation of fibrinogen modulates the activity and binding of FGF-2 that involves a site near the carboxyl terminus of the gamma chain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871330     DOI: 10.1046/j.1538-7836.2003.00228.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Antiangiogenic activity of rPAI-1(23) promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism.

Authors:  Jessica Mollmark; Saranya Ravi; Baiming Sun; Samantha Shipman; Maarten Buitendijk; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Circ Res       Date:  2011-05-05       Impact factor: 17.367

2.  Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice.

Authors:  Jessica I Mollmark; Andrew J-H Park; Justin Kim; Thomas Z Wang; Sarah Katzenell; Samantha L Shipman; Lyubomir G Zagorchev; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-13       Impact factor: 8.311

3.  Influence of Interleukin-1 Beta on Platelet-Poor Plasma Clot Formation: A Potential Impact on Early Bone Healing.

Authors:  Xin Wang; Yan Luo; Paul P Masci; Ross Crawford; Yin Xiao
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

4.  Alteration of blood clot structures by interleukin-1 beta in association with bone defects healing.

Authors:  Xin Wang; Thor E Friis; Paul P Masci; Ross W Crawford; Wenbo Liao; Yin Xiao
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

5.  Endothelialization of an ePTFE vessel prosthesis modified with an antithrombogenic fibrin/heparin coating enriched with bound growth factors.

Authors:  Johanka Táborská; Zuzana Riedelová; Eduard Brynda; Pavel Májek; Tomáš Riedel
Journal:  RSC Adv       Date:  2021-02-03       Impact factor: 3.361

Review 6.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.